FDA approves Retatrutide this year?

According to the latest prediction market data for the query “FDA approves Retatrutide this year?”, traders have formed a strong consensus.

Currently, No is dominating the market with an overwhelming 88.5% chance of winning. Yes follows in second place at 11.5%. The betting volume for this specific market has already reached $569.8K, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• No (88.5%): Currently commanding the highest probability, No is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 89¢, signaling a high degree of market conviction.

🥈 Tier 2: The Primary Challengers

• Yes (11.5%): Positioned as the most viable alternative, Yes maintains a 11.5% chance of resolving true. Its “Buy Yes” shares currently trade at 12¢.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)

For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced

For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)

For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:

Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:

Approvable letters that require additional actions before approval

Tentative approvals pending patent or exclusivity expiration

FDA requests for additional information or studies

Extension of Prescription Drug User Fee Amendments dates

Approval for compassionate use or expanded access programs only

Approval only for export or for use outside the United States

Emergency Use Authorization (EUA) without full approval

Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

While human consensus and speculative volume shape the broader prediction market, our quantitative algorithms offer a data-driven counter-perspective. By analyzing fundamental signals, underlying trends and historical distributions, our AI Valuation model calculates an independent “Fair Value” probability for each outcome.

Comparing this Fair Value against the current Trade Value uncovers major disparities — known as the Expected Value (EV) Gap. Contracts with a positive EV Gap represent statistically underpriced outcomes, whereas a negative EV Gap flags a potential market overreaction.

Top AI Alpha & Mispriced Arbitrage Opportunities

Based on the latest data model run, several key contracts stand out with significant deviations:

• The Most Overvalued Outcome No currently trades at 88.5%, but our AI places its Fair Value at just 82.2%. This creates a large negative EV Gap of -6.3%, suggesting the crowd may be overhyping this outcome and driving the premium too high.
• The Best Value Play (Highest EV) Our model identifies Yes as the premium value opportunity on the board. While the market only assigns it a 11.5% trading probability, our AI’s Fair Value assessment sits at 17.8% — yielding an impressive +6.3% EV Gap.